Sipuleucel-T immunotherapy for castration-resistant prostate cancer

N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Cancer Vaccines / economics
  • Cancer Vaccines / therapeutic use*
  • Combined Modality Therapy
  • Cost-Benefit Analysis
  • Disease Progression
  • Docetaxel
  • Humans
  • Immunotherapy / economics*
  • Male
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / therapy*
  • Taxoids / economics
  • Taxoids / therapeutic use
  • Tissue Extracts / economics
  • Tissue Extracts / therapeutic use*

Substances

  • Antineoplastic Agents
  • Cancer Vaccines
  • Taxoids
  • Tissue Extracts
  • Docetaxel
  • sipuleucel-T